Denmark’s BioInnovation Institute (BII) has launched a €60 million international venture-building programme aimed at accelerating the commercialization of breakthrough research in cardiometabolic diseases across Europe. Backed by funding from the Novo Nordisk Foundation, the initiative seeks to bridge the gap between academic research and successful biotechnology companies by supporting promising scientific discoveries through dedicated funding, infrastructure, and business development.
The programme, known as CardioMetabolic Bridge, is designed to help researchers transform early-stage innovations into scalable healthcare ventures. By connecting leading research institutions with investors, entrepreneurs, and industry experts, the initiative aims to strengthen Europe’s position in life sciences while addressing the growing global burden of obesity, diabetes, and cardiovascular diseases.
International Network Expands Beyond Denmark
As part of the programme, the BioInnovation Institute is expanding its presence beyond Denmark by establishing innovation hubs across Europe. The first international research space has been announced in London, with additional hubs planned in Germany and Italy to create a connected network supporting life science entrepreneurs and university spin-offs.
The expansion reflects a growing emphasis on cross-border collaboration in biotechnology, where scientific discoveries increasingly require international partnerships to progress from laboratory research to commercial healthcare solutions. The hubs will provide access to laboratory facilities, mentorship, business expertise, and investment opportunities for researchers developing innovative therapies and technologies.
The programme is specifically focused on cardiometabolic diseases, one of the world’s fastest-growing healthcare challenges. Rising rates of obesity, diabetes, and cardiovascular conditions have increased demand for innovative treatments, preventive technologies, and precision medicine approaches. By supporting early-stage ventures, the initiative aims to accelerate the development of solutions capable of improving patient outcomes while strengthening Europe’s biotechnology ecosystem.
Bridging the Gap Between Research and Commercialization
One of the primary objectives of the initiative is to overcome the challenges researchers often face when moving scientific discoveries from universities into commercial markets. Many promising innovations struggle to secure early-stage funding, business expertise, and industry connections needed to become viable companies.
Through the CardioMetabolic Bridge programme, selected research teams will receive venture-building support that combines scientific development with commercial strategy, intellectual property guidance, leadership development, and access to investors. This integrated approach is intended to reduce the risks associated with early-stage biotechnology innovation while improving the likelihood of successful commercialization.
The BioInnovation Institute has built a strong reputation for supporting startups working in human health, planetary health, and societal resilience. The latest investment further expands its mission by creating a broader European platform capable of nurturing high-impact biotechnology companies from their earliest stages.
Europe Strengthens Its Life Sciences Ecosystem
The €60 million programme reflects Europe’s growing commitment to strengthening its biotechnology and health innovation sectors through coordinated investment in research commercialization. Governments, research organizations, and private foundations are increasingly recognizing that transforming academic discoveries into successful businesses is essential for improving healthcare while supporting economic growth.
Cardiometabolic diseases continue to represent one of the largest global healthcare challenges, driving demand for new medicines, diagnostics, and digital health solutions. Programmes that combine funding with entrepreneurial support are expected to play an increasingly important role in accelerating scientific breakthroughs and attracting investment into life sciences.
By establishing an international innovation network and supporting researchers through every stage of commercialization, the BioInnovation Institute aims to create a stronger pipeline of biotechnology companies capable of delivering next-generation healthcare solutions. The initiative also reinforces Denmark’s growing reputation as a leading European hub for life science research, innovation, and startup development while encouraging greater collaboration across the continent’s research ecosystem.